Information Provided By: 
Fly News Breaks for February 22, 2018
MNTA
Feb 22, 2018 | 07:13 EDT
As previously reported, Stifel analyst Alex Schwartz upgraded Momenta to Buy from Hold, stating that he believes the company's progress in its novel pipeline outweighs the highly competitive marketplace for generic Copaxone. He thinks January's M281 data that showed over 80% reduction in IgG level and a clean safety profile is "compelling" and that M281 is valuable, he tells investors, noting that he has now added the drug to his model. Schwartz raised his price target on Momenta shares to $21 from $18.
News For MNTA From the Last 2 Days
There are no results for your query MNTA
